Prognostic Factors for Permanent Work Disability in Patients With Rheumatoid Arthritis Who Received Combination Therapy of Conventional Synthetic Disease-Modifying Antirheumatic Drugs
Authors:
- M. Luisa Vazquez-VillegasMVM. Luisa Vazquez-Villegas
- Jorge I. Gamez-NavaJGJorge I. Gamez-Nava
- Liliana F. de la Cerda-TrujilloLCLiliana F. de la Cerda-Trujillo
- Jessica D. Murillo-VazquezJMJessica D. Murillo-Vazquez
- A. Miriam Saldaña-CruzASA. Miriam Saldaña-Cruz
- Miriam F. Alcaraz-LopezMAMiriam F. Alcaraz-Lopez
- Valeria Diaz-RizoVDValeria Diaz-Rizo
- Jose Alvarez-NemegyeiJAJose Alvarez-Nemegyei
- Mario H. CardielMCMario H. Cardiel
- Laura Gonzalez-LopezLGLaura Gonzalez-Lopez
- 1 October 2017
- journal article
- research article
- Published by Wolters Kluwer Health in JCR: Journal of Clinical Rheumatology
- Vol. 23 (7) , 376-382
Abstract
Background: There is limited information about the factors related with the development of long-term permanent work disability (PWD) in rheumatoid arthritis (RA) treated with a combination of conventional synthetic disease-modifying antirheumatic drugs (cs-DMARDs). Objective: The aim of this study was to evaluate incidence and factors associated with the development of PWD in RA treated with combination therapy using conventional synthetic cs-DMARDs. Methods: We assessed in multivariate models the effect of clinical and demographic factors in the development of PWD in a long-term retrospective cohort of 180 workers with RA who were treated with a combination of cs-DMARDs. Results: Incidence rates of PWD were 2.2% at 1 year, 7.7% at 5 years, 24.9% at 10 years, 34.9% at 15 years, and 45% at 20 years. In the adjusted Cox regression analysis, factors associated with PWD development were the first failure with combination of cs-DMARDs (hazard ratio [HR], 2.4; 95% confidence interval [CI], 1.05–5.46; P = 0.03), poor functioning at time of cohort onset (HR, 2.2; 95% CI, 1.05–4.70; P = 0.03), and requirement for joint replacement (HR, 3.3; 95% CI, 1.28–8.79; P = 0.01). Conclusions: Around 25% of workers with combination therapy with cs-DMARDs developed PWD in 10 years following the diagnosis of RA. Some factors increase the risk of disability. Permanent work disability generates a relevant society burden and increases health care costs. Therefore, indicators predicting failure of combination therapies with cs-DMARDs might provide clinicians of useful tools for modifying treatments avoiding the disease progression.Keywords
This publication has 22 references indexed in Scilit:
- Actualización de la Guía Mexicana para el Tratamiento Farmacológico de la Artritis Reumatoide del Colegio Mexicano de ReumatologíaReumatología Clínica, 2014
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateAnnals of the Rheumatic Diseases, 2014
- Associations of disease activity and treatments with mortality in men with rheumatoid arthritis: results from the VARA registryRheumatology, 2010
- Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritisRheumatology, 2007
- Sick leave as a predictor of job loss in patients with chronic arthritisInternational Archives of Occupational and Environmental Health, 2006
- High work disability rate among rheumatoid arthritis patients in LithuaniaArthritis Care & Research, 2004
- Employment and work disability in rheumatoid arthritisCurrent Opinion in Rheumatology, 2004
- Epidemiology of rheumatic diseasesRheumatology, 2000
- Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritisArthritis & Rheumatism, 2000
- Work disability in an inception cohort of patients with seropositive rheumatoid arthritis: a 20 year studyRheumatology, 1999